1. Home
  2. BATRK vs ARQT Comparison

BATRK vs ARQT Comparison

Compare BATRK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series C

BATRK

Atlanta Braves Holdings Inc. Series C

HOLD

Current Price

$52.76

Market Cap

3.4B

Sector

Industrials

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$28.22

Market Cap

3.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRK
ARQT
Founded
1991
2016
Country
United States
United States
Employees
N/A
354
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.2B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
BATRK
ARQT
Price
$52.76
$28.22
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$60.00
$34.00
AVG Volume (30 Days)
401.8K
2.2M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
26.00
88.79
EPS
N/A
0.03
Revenue
$732,492,000.00
$376,072,000.00
Revenue This Year
$12.40
$34.85
Revenue Next Year
$8.54
$29.39
P/E Ratio
N/A
$865.33
Revenue Growth
10.52
91.34
52 Week Low
$37.76
$16.68
52 Week High
$54.46
$31.77

Technical Indicators

Market Signals
Indicator
BATRK
ARQT
Relative Strength Index (RSI) 59.05 56.61
Support Level $48.61 $24.91
Resistance Level $52.40 $27.57
Average True Range (ATR) 1.01 1.13
MACD 0.23 0.34
Stochastic Oscillator 93.82 85.34

Price Performance

Historical Comparison
BATRK
ARQT

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: